DEFA14A: ATAI Advances Beckley Psytech Acquisition, BPL-003 Shines

ATAI Life Sciences is moving forward with its acquisition of Beckley Psytech, which reported increased losses but positive Phase 2b results for BPL-003 and secured $10M funding.

Summary

• ATAI Life Sciences N.V. (atai) is proceeding with the acquisition of the remaining issued share capital of Beckley Psytech Limited (Beckley Psytech) not already owned by atai.
• The transaction is expected to close in the fourth quarter of 2025, contingent on atai shareholder approval and other customary closing conditions.
• Beckley Psytech reported a total comprehensive loss of £20.26 million for the six months ended June 30, 2025, a significant increase from £7.49 million for the same period in 2024.
• Operating loss for H1 2025 rose to £30.75 million from £19.28 million in H1 2024, primarily driven by a £14.12 million loss on contingent consideration.
• Cash and cash equivalents decreased to £1.62 million as of June 30, 2025, down from £5.08 million at December 31, 2024.
• Beckley Psytech announced positive topline results on July 1, 2025, for its BPL-003-201 Phase 2b study, which met its primary and all key secondary endpoints.
• ATAI provided a $10.0 million senior promissory note to Beckley Psytech on August 13, 2025, with funds received on August 15, 2025, to support BPL-003 development milestones.
• Beckley Psytech intends to spin off Eleusis and its subsidiaries to its existing shareholders prior to the completion of the acquisition.

Sentiment

Score: 5

Explanation: While Beckley Psytech's financial performance for H1 2025 shows a significant increase in losses and a precarious cash position, the positive Phase 2b results for BPL-003 are a major clinical de-risking event. The ongoing acquisition by ATAI and the $10 million promissory note provide a lifeline and a clear path for the company's future, mitigating immediate solvency concerns, but the explicit 'material uncertainty' regarding going concern remains a significant negative.

Positives

• Positive topline results for the BPL-003-201 Phase 2b study were announced on July 1, 2025, meeting its primary and all key secondary endpoints, demonstrating rapid, robust, and durable antidepressant effects with a single dose.
• Secured $10.0 million in funding from atai via a promissory note for BPL-003 development milestones, with the full amount received on August 15, 2025.
• Net cash used in operating activities improved to (£3.29 million) for the six months ended June 30, 2025, compared to (£26.89 million) for the same period in 2024.
• Recognized a significant gain on revaluation of warrants of £6.77 million in H1 2025, reflecting the high probability of the acquisition closing and the subsequent extinguishment of these warrants.

Negatives

• Total comprehensive loss more than doubled to £20.26 million for the six months ended June 30, 2025, from £7.49 million in the prior year period.
• Operating loss increased to £30.75 million in H1 2025 from £19.28 million in H1 2024, largely due to a £14.12 million loss on contingent consideration.
• Cash and cash equivalents significantly decreased to £1.62 million as of June 30, 2025, from £5.08 million at December 31, 2024.
• Existing resources are not sufficient to fund ongoing operations for at least 12 months without additional financing, even with the $10.0 million promissory note, requiring a significant reduction in cash spend.
• A material uncertainty exists regarding the ability to continue as a going concern due to reliance on the acquisition closing, atai providing adequate financing, and timely receipt of R&D tax credits.

Risks

• The proposed acquisition by atai may not be completed in a timely manner or at all, including the risk that required shareholder approvals are not obtained.
• Failure to realize the anticipated benefits of the proposed acquisition.
• The possibility that any or all of the various conditions to the consummation of the proposed acquisition may not be satisfied or waived.
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the Share Purchase Agreement.
• The effect of the announcement or pendency of the proposed acquisition on atai's ability to retain and hire key personnel, or its operating results and business generally.
• Material uncertainty regarding Beckley Psytech's ability to continue as a going concern if the acquisition does not close, atai does not provide adequate financing, R&D tax credits are delayed, or cash spend reduction is not implemented.
• Potential for impairment of the Eleusis In-Process Research & Development (IPR&D) if commercialization probability decreases, discount rate increases, time to commercialization is further delayed, or annual revenue decreases.
• Future cash flows and the recoverable amount of the Eleusis intangible asset could materially change if management pursues an alternative indication for the Eleusis CGU.

Future Outlook

The acquisition of Beckley Psytech by ATAI is expected to close in the fourth quarter of 2025, subject to shareholder approval and customary conditions. Beckley Psytech intends to spin off its Eleusis subsidiary prior to the acquisition. Management is also considering an alternative indication for the Eleusis CGU, which could materially alter its future cash flows. The company's ability to continue as a going concern is dependent on the acquisition closing, ATAI providing further financing, and timely receipt of R&D tax credits, alongside a significant reduction in cash burn.

Management Comments

• "Management has prepared a cash flow forecast for the Group and has considered the ability for the Group to continue as a going concern for the foreseeable future, being at least 12 months after approving these financial statements."
• "Based on the cash and cash equivalents on hand as at the date this report is available for issue, the directors forecast that without additional financing, current existing resources will not be sufficient to fund its ongoing operations for at least 12 months after approving these financial statements."
• "Accordingly, the directors have prepared the Interim Condensed Consolidated Financial Statements on a going concern basis due to the fact that it is the expectation of the directors that the Acquisition will conclude and additional financing required will be provided by Atai, that R&D tax credits are expected to be received under the normal operations of the business, and cash spend will be significantly reduced within the going concern period."
• "However, there is no guarantee that the Acquisition will conclude and that Atai will provide adequate financing to the Group following the closing of the transaction, nor that other additional funding or the R&D tax credits will be received in time to enact the business plan. The inability to close the Acquisition or obtain additional funding by some other means, a delay in the receipt of R&D tax credits or a delay or inability to implement a reduction in cash spend could impact the Groups financial condition and ability to pursue its business strategies, including being required to delay, reduce or eliminate some of its research and development programs, or result in the Group being unable to meet their obligations as they fall due or continue operations. This represents a material uncertainty that may cast significant doubt about the Groups ability to continue as a going concern."
• "Subsequent to the period end, management have been considering the strategic direction of the In Process Research and Development associated with the Eleusis CGU and focusing on an alternative indication. This decision could materially change the future cashflows and therefore the recoverable amount of the related intangible asset in future periods."

Industry Context

The psychedelic-assisted therapy industry is an emerging field with significant R&D investment and high regulatory hurdles. Companies like Beckley Psytech are at the forefront of developing novel treatments for mental health conditions. The acquisition by ATAI, a prominent player in the psychedelic drug development space, signifies consolidation and strategic alignment within the industry, aiming to leverage synergies and accelerate drug pipelines. The positive Phase 2b results for BPL-003 are a crucial de-risking event in a sector where clinical success is paramount for investor confidence and future commercialization. The ongoing need for significant capital, as evidenced by Beckley Psytech's financial position and reliance on ATAI's funding, is characteristic of early-stage biotech companies in this capital-intensive sector.

Comparison to Industry Standards

• Beckley Psytech's significant operating losses and negative cash flow are typical for a pre-revenue biotechnology company heavily invested in research and development, especially in the capital-intensive psychedelic drug development space.
• The positive Phase 2b results for BPL-003 are a strong indicator of clinical progress, comparable to successful mid-stage trial outcomes reported by peers like COMPASS Pathways (psilocybin for TRD) or MindMed (LSD-based therapies), which often lead to increased investor confidence and potential for further development.
• The reliance on a larger strategic investor (ATAI) for continued funding and the eventual acquisition is a common pathway for smaller biotech firms to secure necessary capital and expertise to advance their pipelines, similar to how larger pharmaceutical companies acquire promising smaller biotechs.
• The 'material uncertainty' regarding going concern, despite the promissory note, highlights the inherent financial risks in drug development, where funding is often milestone-dependent and subject to market conditions and clinical outcomes.

Related Party Transactions

• ATAI Life Sciences N.V. holds 33.64% of Beckley Psytech's shares and can appoint 3 board members.
• On January 3, 2024, Beckley Psytech issued 24,096,385 Series C shares for $40 million to ATAI, with $15 million initially held in escrow.
• The remaining $10.5 million (including interest) from the escrow account was fully drawn down by Beckley Psytech on April 1, 2025.
• ATAI and Beckley Psytech entered into a senior promissory note on August 13, 2025, for up to $10.0 million, received by Beckley Psytech on August 15, 2025.

Stakeholder Impact

• Shareholders (ATAI): Will gain full ownership of Beckley Psytech, integrating its pipeline, particularly BPL-003, into ATAI's portfolio. Subject to shareholder approval for the acquisition.
• Shareholders (Beckley Psytech): Will receive consideration for their shares from ATAI and will also receive a pro-rata equity holding in Eleusis via a spin-off.
• Employees (Beckley Psytech): Integration into ATAI could bring stability and resources, but also potential for organizational changes.
• Customers/Patients: Potential for accelerated development and eventual availability of BPL-003 for mental health conditions.
• Creditors: The $10.0 million promissory note from ATAI and the anticipated acquisition provide a more stable financial outlook, reducing immediate credit risk, though the going concern uncertainty remains.

Next Steps

• ATAI shareholders to approve the acquisition of Beckley Psytech.
• Completion of the acquisition of Beckley Psytech by ATAI, expected in Q4 2025.
• Spin-off of Eleusis and its subsidiaries to existing Beckley Psytech shareholders prior to the acquisition.
• Eleusis to raise funding as a standalone company before commencing its trial.
• Beckley Psytech to achieve certain development milestones for BPL-003 using the $10.0 million promissory note.
• Management to implement a significant reduction in cash spend to extend cash runway.
• Management to continue considering the strategic direction of the Eleusis CGU, potentially focusing on an alternative indication.

Key Dates

Recommendation

While Beckley Psytech's financial results for H1 2025 show a significant deterioration in losses and a critical cash position, the positive Phase 2b clinical trial results for BPL-003 are a substantial de-risking event for a key asset. The ongoing acquisition by ATAI, a major shareholder, and the recent $10 million promissory note provide a clear path for continued funding and development, mitigating immediate solvency concerns. However, the explicit 'material uncertainty' regarding going concern, the reliance on shareholder approval for the acquisition, and the need for significant cash burn reduction introduce considerable risk. For existing investors, holding is appropriate to see the acquisition through and monitor BPL-003's continued development under ATAI's ownership. New investors might find the risk/reward balanced but should be aware of the financial fragility prior to the acquisition's completion.

Keywords

ATAI Life Sciences, Beckley Psytech, Acquisition, BPL-003, Psychedelics, Mental Health, Clinical Trials, Phase 2b, Drug Development, Biotechnology, SEC Filing, Financial Results, Going Concern, Eleusis, Promissory Note